Initial results of the FUSION-X-US prototype combining 3D automated breast ultrasound and digital breast tomosynthesis

2018 ◽  
Vol 28 (6) ◽  
pp. 2499-2506 ◽  
Author(s):  
Benedikt Schaefgen ◽  
Joerg Heil ◽  
Richard G. Barr ◽  
Marcus Radicke ◽  
Aba Harcos ◽  
...  
2020 ◽  
Vol 2 (2) ◽  
pp. 125-133 ◽  
Author(s):  
Denise M Chough ◽  
Wendie A Berg ◽  
Andriy I Bandos ◽  
Grace Y Rathfon ◽  
Christiane M Hakim ◽  
...  

Abstract Objective To assess prospectively the interpretative performance of automated breast ultrasound (ABUS) as a supplemental screening after digital breast tomosynthesis (DBT) or as a standalone screening of women with dense breast tissue. Methods Under an IRB-approved protocol (written consent required), women with dense breasts prospectively underwent concurrent baseline DBT and ABUS screening. Examinations were independently evaluated, in opposite order, by two of seven Mammography Quality Standards Act–qualified radiologists, with the primary radiologist arbitrating disagreements and making clinical management recommendations. We report results for 1111 screening examinations (598 first year and 513 second year) for which all diagnostic workups are complete. Imaging was also retrospectively reviewed for all cancers. Statistical assessments used a 0.05 significance level and accounted for correlation between participants’ examinations. Results Of 1111 women screened, primary radiologists initially “recalled” based on DBT alone (6.6%, 73/1111, CI: 5.2%–8.2%), of which 20 were biopsied, yielding 6/8 total cancers. Automated breast ultrasound increased recalls overall to 14.4% (160/1111, CI: 12.4%–16.6%), with 27 total biopsies, yielding 1 additional cancer. Double reading of DBT alone increased the recall rate to 10.7% (119/1111), with 21 biopsies, with no improvement in cancer detection. Double reading ABUS increased the recall rate to 15.2% (169/1111, CI: 13.2%–17.5%) of women, of whom 22 were biopsied, yielding the detection of 7 cancers, including one seen only on double reading ABUS. Inter-radiologist agreement was similar for recall recommendations from DBT (κ = 0.24, CI: 0.14–0.34) and ABUS (κ = 0.23, CI: 0.15–0.32). Integrated assessments from both readers resulted in a recall rate of 15.1% (168/1111, CI: 13.1%–17.4%). Conclusion Supplemental or standalone ABUS screening detected cancers not seen on DBT, but substantially increased noncancer recall rates.


2018 ◽  
Vol 45 (10) ◽  
pp. 4402-4417 ◽  
Author(s):  
Crystal A. Green ◽  
Mitchell M. Goodsitt ◽  
Kristy K. Brock ◽  
Cynthia L. Davis ◽  
Eric D. Larson ◽  
...  

2020 ◽  
Vol 60 ◽  
pp. 101599 ◽  
Author(s):  
Crystal A. Green ◽  
Mitchell M. Goodsitt ◽  
Marilyn A. Roubidoux ◽  
Kristy K. Brock ◽  
Cynthia L. Davis ◽  
...  

Author(s):  
Lamiaa Mohamed Bassam Hashem ◽  
Reham Hussein Mohamed Ali ◽  
Maha Hussein Helal ◽  
Emad ELdin E. L. Gemeae ◽  
Amr Farouk Ibrahim Moustafa

Author(s):  
Benedikt Schäfgen ◽  
Marija Juskic ◽  
Marcus Radicke ◽  
Madeleine Hertel ◽  
Richard Barr ◽  
...  

Abstract Objective The FUSION-X-US-II prototype was developed to combine 3D automated breast ultrasound (ABUS) and digital breast tomosynthesis in a single device. We evaluated the performance of ABUS and tomosynthesis in a single examination in a clinical setting. Methods In this prospective feasibility study, digital breast tomosynthesis and ABUS were performed using the FUSION-X-US-II prototype without any change of the breast position in patients referred for clarification of breast lesions with an indication for tomosynthesis. The tomosynthesis and ABUS images of the prototype were interpreted independently from the clinical standard by a breast diagnostics specialist. Any detected lesion was classified using BI-RADS® scores, and results of the standard clinical routine workup (gold standard) were compared to the result of the separate evaluation of the prototype images. Image quality was rated subjectively and coverage of the breast was measured. Results One hundred one patients received both ABUS and tomosynthesis using the prototype. The duration of the additional ABUS acquisition was 40 to 60 s. Breast coverage by ABUS was approximately 80.0%. ABUS image quality was rated as diagnostically useful in 86 of 101 cases (85.1%). Thirty-three of 34 malignant breast lesions (97.1%) were identified using the prototype. Conclusion The FUSION-X-US-II prototype allows a fast ABUS scan in combination with digital breast tomosynthesis in a single device integrated in the clinical workflow. Malignant breast lesions can be localized accurately with direct correlation of ABUS and tomosynthesis images. The FUSION system shows the potential to improve breast cancer screening in the future after further technical improvements. Key Points • The FUSION-X-US-II prototype allows the combination of automated breast ultrasound and digital breast tomosynthesis in a single device without decompression of the breast. • Image quality and coverage of ABUS are sufficient to accurately detect malignant breast lesions. • If tomosynthesis and ABUS should become part of breast cancer screening, the combination of both techniques in one device could offer practical and logistic advantages. To evaluate a potential benefit of a combination of ABUS and tomosynthesis in screening-like settings, further studies are needed.


2018 ◽  
Vol 44 (3) ◽  
pp. 734-742 ◽  
Author(s):  
Eric D. Larson ◽  
Won-Mean Lee ◽  
Marilyn A. Roubidoux ◽  
Mitchell M. Goodsitt ◽  
Chris Lashbrook ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document